Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada approves Cardiac Science's Powerheart:

This article was originally published in Clinica

Executive Summary

Cardiac Science has received the go-ahead to market its Powerheart hospital bedside defibrillator-monitor in Canada. The fully automatic device detects the onset of a life-threatening arrhythmias and delivers defibrillation in seconds without the aid of hospital staff. The product is already cleared for sale in Australia, Europe and in the US. The Irvine, California-based company says it began marketing the device in early 2000 since when, it has generated around $4.2 million in revenue based on the sale of 734 Powerheart systems and related accessories.

You may also be interested in...



Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

Novartis Targets Ten Indications For Cosentyx

The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.

Zydus Cadila Strides Ahead With NASH Filing In India

Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.

 

Topics

UsernamePublicRestriction

Register

MT070350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel